Arena Pharmaceuticals, Inc.
Oct 11, 2004

Arena Pharmaceuticals to Announce Third Quarter 2004 Financial Results and to Host Conference Call and Webcast on Wednesday, October 20, 2004

SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the company will release third quarter 2004 financial results after the NASDAQ National Market closes on Wednesday, October 20, 2004. Arena also announced today that Jack Lief, President and Chief Executive Officer of Arena, will host a conference call to discuss the financial results and corporate highlights from the third quarter. The call will take place on October 20, 2004, at 5:00 PM Eastern Time (2:00 PM Pacific Time).

The conference call may be accessed by dialing (888) 273-9887 for domestic callers and (612) 332-0634 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals Third Quarter Earnings Conference Call." The conference call will be webcast live on Arena's website at, under the investor relations section, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a biopharmaceutical company focusing on the discovery, development and commercialization of drugs in four major therapeutic areas: metabolic, cardiovascular, inflammatory and central nervous system diseases. Arena is developing a broad pipeline of compounds that act on an important class of drug targets called G protein-coupled receptors, or GPCRs, and that are being developed using Arena's proprietary technologies, including CART (Constitutively Activated Receptor Technology) and Melanophore. Arena also has research collaborations with Merck, Fujisawa, Taisho and TaiGen for products in a number of different indications. For additional information about Arena, visit their website at

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, technologies, preclinical and clinical programs, ability to identify and develop drugs, future achievements, goals and expectations, as well as other statements that are not historical facts. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena's research, out-licensing endeavors and clinical studies, Arena's ability to obtain additional financing, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's SEC reports, including Arena's most recent quarterly report on Form 10-Q. These forward-looking statements represent Arena's judgment as of the date of this release. Arena disclaims any intent or obligation to update these forward-looking statements.

Arena Pharmaceuticals® and Arena® are registered service marks of the company. CART is an unregistered service mark of the company.

SOURCE Arena Pharmaceuticals, Inc.
CONTACT: Jack Lief, President & CEO of Arena Pharmaceuticals, +1-858-453-7200; or Susan Neath, Media & Investor Relations of Atkins + Associates, +1-858-527-3486, for Arena Pharmaceuticals
Web site: